Efficacy of Beraprost Sodium Combined with Agatroban in the Treatment of Patients with Acute Cerebral Infarction and Its Effects on Cognitive Function and Serum Inflammatory Factors
OBJECTIVE:To probe into the efficacy of beraprost sodium combined with agatroban in the treatment of patients with acute cerebral infarction(ACI)and its effects on cognitive function and serum inflammatory factors.METHODS:From Dec.2022 to Nov.2023,a total of 126 patients with ACI admitted into the hospital were extracted to be divided into the combined treatment group and agatroban group via the random number table method,with 63 cases in each group.The agatroban group was treated with routine symptomatic therapy and agatroban,while the combined treatment group received beraprost sodium on the basis of agatroban group.The clinical efficacy and adverse drug reactions of two groups were recorded,and the cognitive function,levels of inflammatory factors,oxidative stress indicators,and cerebral hemodynamic indicators were compared between two groups.RESULTS:The total clinical effective rate of the combined treatment group was 88.89%(56/63),significantly higher than 74.60%(47/63)in the agatroban group,with statistically significant difference(P<0.05).After treatment,the Montreal Cognitive Assessment(MoCA)and the Mini-Mental State Examination(MMSE)scores in both groups increased,and the scores MoCA and MMSE in the combined treatment group were significantly higher than those in the agatroban group,with statistically significant difference(P<0.05).After treatment,the levels of tumor necrosis factor-ɑ(TNF-ɑ),interleukin-1β(IL-1β),interleukin-6(IL-6),and C-reactive protein(CRP)in both groups decreased,and the levels of TNF-ɑ,IL-1β,IL-6 and CRP in the combined treatment group were significantly lower than those in the agatroban group,with statistically significant difference(P<0.05).After treatment,the levels of malondialdehyde(MDA)in both groups decreased,while the levels of superoxide dismutase(SOD),total antioxidant capacity(T-AOC)and glutathione peroxidase(GSH-Px)increased significantly,the MDA level in the combined treatment group was significantly lower than that in the agatroban group,while the levels of SOD,T-AOC,and GSH-Px were significantly higher than those in the agatroban group,with statistically significant differences(P<0.05).After treatment,the mean velocity of blood flow(Vmean)and mean blood flow(Qmean)of two groups increased significantly,while the vascular resistance(Rv)and characteristic impedance of cerebrovascular net(Zcv)decreased significantly;compared with agatroban group,Vmean and Qmean increased more significantly,Rv and Zcv decreased more significantly in the combined treatment group,with statistically significant differences(P<0.05).There was no statistically significant difference in the total incidence of adverse drug reactions between two groups(P>0.05).CONCLUSIONS:Ceraprost sodium combined with agatroban in the treatment of patients with acute cerebral infarction can effectively improve the efficiency,reduce inflammatory and oxidative stress reactions,improve cognitive function and cerebral hemodynamic indicators,with higher medication safety.
国家科技期刊平台
NSTL
万方数据
